BRÈVE

sur ABIVAX (EPA:ABVX)

ABIVAX announces an update on its share capital and voting rights

On February 23, 2024, ABIVAX (Euronext Paris: FR0012333284 - ABVX), a biotechnology company focused on developing treatments for chronic inflammatory diseases, disclosed the number of shares making up its share capital as well as the total count of its voting rights as of January 31, 2024. The company's capital amounts to €629,288.18, represented by 62,928,818 shares. In terms of voting rights, the theoretical total stands at 69,938,767, while the number of exercisable voting rights is 69,927,438.

Through this announcement, ABIVAX complies with regulatory requirements regarding financial transparency, providing a clear view to shareholders and the market. This update highlights the company's governance structure and its commitment to following the recommendations of the French Financial Markets Authority (Autorité des Marchés Financiers). ABIVAX continues its development, notably with its flagship drug, obefazimod (ABX464), actively in phase 3 for the treatment of ulcerative colitis.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de ABIVAX